Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4134 - First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma


09 Oct 2016


Poster display


Elisa De Carlo


Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367


E. De Carlo1, L. Gurrieri2, G. De Maglio3, L. Gerratana1, V. Buoro1, S. Rizzato1, M. Isola4, M. Skrap5, G. Fasola1, F. Puglisi1, S. Pizzolitto3

Author affiliations

  • 1 Department Of Oncology, University Hospital of Udine, 33100 - Udine/IT
  • 2 Department Of Oncology, Ospedale dell'Angelo, Mestre/IT
  • 3 Department Of Pathology, University Hospital of Udine, 33100 - Udine/IT
  • 4 Department Of Medical And Biological Sciences, University of Udine, 33100 - Udine/IT
  • 5 Department Of Neurosurgery, University Hospital of Udine, 33100 - Udine/IT


Abstract 4134


Epigenetic variations in the O6-methylguanine-methyltransferase (MGMT) gene had been widely associated with a favorable impact on survival in patients (pts) affected by glioblastoma (GBM). MGMT includes 98 CpG islands (CpGi) and patterns of methylation are rather heterogeneous. Aim of this study is to explore a scoring system based on the gene promoter methylation in order to predict pts' prognosis.


The study analyzed a series of 121 pts with GBM treated at the University Hospital of Udine between 2008 and 2014. The methylation level of CpGi from 74 to 83 was analyzed through pyrosequencing. In accordance to previous literature, each island was assigned with 1 point if the corresponding methylation level was higher than 9%. The sum consisted in a score that went from 0 (all CpGi = 9%). A training set of 75 pts was randomly generated. A threshold capable to detect a favorable outcome (OS > 24 months) was identified by ROC analysis. The prognostic impact was explored through Cox regression. The results were verified on a validation set of 46 pts.


Median OS was 14 months. Among the total population 35% of the pts had a score of 0, while 29% had a score of 10. The score's prognostic impact was confirmed also by comparison with the methylation mean and median through stepwise Cox regression (P= 0.0002). The threshold identified was 6 (AUC 0.74). On univariate analysis, a score > 6 was associated with a favorable prognosis both in the training and in the validation set (HR 0.42, 95%CI 0.23-0.77, P= 0.0046; HR 0.37, 95%CI 0.18-0.77, P = 0.0078; respectively). The result was maintained also in multivariate analysis of the whole population (HR 0.43, 95%CI 0.27-0.67, P = 0.0002) when corrected for age (>70 vs ≤ 70 years HR 2.19, 95%CI 1.30-3.69, P = 0.0032) and ECOG performance status (0-1 vs 2-3 HR 2.20, 95%CI 1.36-3.54, P = 0.0012). Similar results were observed also in terms of PFS.


The present study explored a novel scoring system capable to take into consideration the methylation status of single CpGi. Since the limited prognostic significance of each CpGi, combining the information from multiple CpGi is crucial in order to better predict prognosis in GBM patients.

Clinical trial identification

Legal entity responsible for the study

University Hospital of Udine




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings